https://scholars.lib.ntu.edu.tw/handle/123456789/580037
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Finn R.S. | en_US |
dc.contributor.author | Ryoo B.-Y. | en_US |
dc.contributor.author | Merle P. | en_US |
dc.contributor.author | Kudo M. | en_US |
dc.contributor.author | Bouattour M. | en_US |
dc.contributor.author | Lim H.Y. | en_US |
dc.contributor.author | Breder V. | en_US |
dc.contributor.author | Edeline J. | en_US |
dc.contributor.author | Chao Y. | en_US |
dc.contributor.author | Ogasawara S. | en_US |
dc.contributor.author | Yau T. | en_US |
dc.contributor.author | Garrido M. | en_US |
dc.contributor.author | Chan S.L. | en_US |
dc.contributor.author | Knox J. | en_US |
dc.contributor.author | Daniele B. | en_US |
dc.contributor.author | Ebbinghaus S.W. | en_US |
dc.contributor.author | Chen E. | en_US |
dc.contributor.author | Siegel A.B. | en_US |
dc.contributor.author | Zhu A.X. | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | KEYnote-240 investigators | en_US |
dc.date.accessioned | 2021-08-31T06:29:19Z | - |
dc.date.available | 2021-08-31T06:29:19Z | - |
dc.date.issued | 2020 | - |
dc.identifier.issn | 1527-7755 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85077942597&doi=10.1200%2fJCO.19.01307&partnerID=40&md5=1179f56ba3aac953bdea882a25d0b0bf | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/580037 | - |
dc.description.abstract | PURPOSE: Pembrolizumab demonstrated antitumor activity and safety in the phase II KEYNOTE-224 trial in previously treated patients with advanced hepatocellular carcinoma (HCC). KEYNOTE-240 evaluated the efficacy and safety of pembrolizumab in this population. PATIENTS AND METHODS: This randomized, double-blind, phase III study was conducted at 119 medical centers in 27 countries. Eligible patients with advanced HCC, previously treated with sorafenib, were randomly assigned at a two-to-one ratio to receive pembrolizumab plus best supportive care (BSC) or placebo plus BSC. Primary end points were overall survival (OS) and progression-free survival (PFS; one-sided significance thresholds, P = .0174 [final analysis] and P = .002 [first interim analysis], respectively). Safety was assessed in all patients who received ? 1 dose of study drug. RESULTS: Between May 31, 2016, and November 23, 2017, 413 patients were randomly assigned. As of January 2, 2019, median follow-up was 13.8 months for pembrolizumab and 10.6 months for placebo. Median OS was 13.9 months (95% CI, 11.6 to 16.0 months) for pembrolizumab versus 10.6 months (95% CI, 8.3 to 13.5 months) for placebo (hazard ratio [HR], 0.781; 95% CI, 0.611 to 0.998; P = .0238). Median PFS for pembrolizumab was 3.0 months (95% CI, 2.8 to 4.1 months) versus 2.8 months (95% CI, 2.5 to 4.1 months) for placebo at the first interim analysis (HR, 0.775; 95% CI, 0.609 to 0.987; P = .0186) and 3.0 months (95% CI, 2.8 to 4.1 months) versus 2.8 months (95% CI, 1.6 to 3.0 months) at final analysis (HR, 0.718; 95% CI, 0.570 to 0.904; P = .0022). Grade 3 or higher adverse events occurred in 147 (52.7%) and 62 patients (46.3%) for pembrolizumab versus placebo; those that were treatment related occurred in 52 (18.6%) and 10 patients (7.5%), respectively. No hepatitis C or B flares were identified. CONCLUSION: In this study, OS and PFS did not reach statistical significance per specified criteria. The results are consistent with those of KEYNOTE-224, supporting a favorable risk-to-benefit ratio for pembrolizumab in this population. | - |
dc.publisher | NLM (Medline) | - |
dc.relation.ispartof | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | immunological antineoplastic agent; monoclonal antibody; pembrolizumab; adolescent; adult; aged; clinical trial; controlled study; double blind procedure; female; human; liver cell carcinoma; liver tumor; male; middle aged; phase 3 clinical trial; randomized controlled trial; very elderly; young adult; Adolescent; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Immunological; Carcinoma, Hepatocellular; Double-Blind Method; Female; Humans; Liver Neoplasms; Male; Middle Aged; Progression-Free Survival; Young Adult | - |
dc.title | Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYnote-240: A Randomized, Double-Blind, Phase III Trial | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1200/JCO.19.01307 | - |
dc.identifier.pmid | 31790344 | - |
dc.identifier.scopus | 2-s2.0-85077942597 | - |
dc.relation.pages | 193-202 | - |
dc.relation.journalvolume | 38 | - |
dc.relation.journalissue | 3 | - |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。